Eosinophilic Granulomatosis With Polyangiitis research hub
3 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study is looking at two medicines, Depemokimab and Mepolizumab, for adults with a rare condition called EGPA. We want to see how well they work and if they are safe when patients are already having standard treatment.
United States · Argentina · Austria - recruiting
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
This study looks for new ways to measure how active a rare condition called Eosinophilic Granulomatosis With Polyangiitis (EGPA) is. EGPA causes asthma, too many white blood cells, and blood vessel inflammation. Better measurements could lead to better treatments.
United States · Canada · Germany - active not recruitingPHASE2
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study is looking into a new medication called NS-229 for Eosinophilic Granulomatosis with Polyangiitis (EGPA), also known as Churg-Strauss Syndrome. We want to see if NS-229 is safe and effective compared to a dummy treatment (placebo) when added to usual care.
United States · Canada · France